We're #hiring! Interested in joining our team of innovators dedicated to developing #Treg therapies for patients with #autoimmune diseases? Check out our open roles here: https://bit.ly/3ScM4CN
Sonoma Biotherapeutics
Biotechnology Research
South San Francisco, California 13,788 followers
Leading the Next Frontier of Cell Therapy
About us
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.
- Website
-
https://www.sonomabio.com
External link for Sonoma Biotherapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
- Specialties
- cell therapy and autoimmune disease
Locations
-
Primary
201 Haskins Way
South San Francisco, California 94080, US
-
410 W Harrison St
Seattle, Washington 98119, US
Employees at Sonoma Biotherapeutics
Updates
-
This week, our Chief Scientific Officer, Joe Arron, M.D., Ph.D., will be giving a presentation on #Treg cell therapy’s potential role in rebalancing the immune system at the BioScience Forum in #SSF. Register to join the event dedicated to providing high-quality educational and networking opportunities for #lifescience professionals & learn more about our mission: https://www.biosf.org/
-
#HidradenitisSuppurativa Awareness Week may be over, but our commitment to the HS community endures year-round. To learn more about our ongoing #clinicaltrial of SBT777101, our engineered CAR-#Treg therapeutic for the potential treatment of HS, visit: https://lnkd.in/gWZuq5RJ.
-
In honor of #HidradenitisSuppurativa (HS) Awareness week, we’re raising awareness for the HS patient community and this painful & chronic condition. Learn more: https://lnkd.in/gjwRrn2J
-
Our employees across #Seattle & #SSF came together for a fantastic day of teamwork, competition, and fun during our annual Whirly Ball Tournament. Congratulations to the winning team! #OneSonoma
-
Our CEO, Jeffrey Bluestone Is looking forward to a full schedule of meetings today at the Jefferies Private Biotech Day in New York City, in conjunction with the Global Healthcare Conference. #JefferiesHealthcare
-
This week, our Vice President, Discovery, Brent McKenzie will be discussing the therapeutic potential of Tregs and strategies for clinical development at the Hanson Wade Group #Treg Directed Therapies Summit in Boston. Learn more about his presentation, and the event discussing groundbreaking research & clinical advancements in Treg therapy: https://lnkd.in/evaCdwM
-
In observance of #AiArthritisDay, our CMO, Mark Eisner, M.D., MPH, shared his insights on the #RheumatoidArthritis treatment landscape, and our work to develop a novel #Treg therapy for the treatment of RA that leverages a patient’s own cells to restore balance to the immune system. Learn more about our work in RA: https://lnkd.in/e3hVmUtt.
-
Today, our Director of Talent, Melisa S. Medrano, PhD, SHRM-CP, will be presenting at the Leap HR #LifeSciences Conference, joining other forward-thinking #biopharma HR leaders to share, discover and initiate change in their organizations. Learn more here: https://lnkd.in/dGq5WNrr
-
Today is the International Day of Immunology. This year's theme, "Immunity Through the Ages," reminds us of the need to understand how our immune system evolves with age. We’re leveraging the complexities of the immune system to have a positive impact on health through development of potential treatments for #RheumatoidArthritis and #HidradenitisSuppurativa. Learn more below. #DayofImmunology #ImmunityThroughAges